GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (CHIX:PHMe) » Definitions » Cyclically Adjusted PS Ratio

Pharma Mar (CHIX:PHME) Cyclically Adjusted PS Ratio : 7.21 (As of Dec. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Pharma Mar Cyclically Adjusted PS Ratio?

As of today (2024-12-12), Pharma Mar's current share price is €68.825. Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was €9.54. Pharma Mar's Cyclically Adjusted PS Ratio for today is 7.21.

The historical rank and industry rank for Pharma Mar's Cyclically Adjusted PS Ratio or its related term are showing as below:

CHIX:PHMe' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.21   Med: 4.2   Max: 14.45
Current: 7

During the past years, Pharma Mar's highest Cyclically Adjusted PS Ratio was 14.45. The lowest was 1.21. And the median was 4.20.

CHIX:PHMe's Cyclically Adjusted PS Ratio is ranked worse than
55.56% of 441 companies
in the Biotechnology industry
Industry Median: 6.15 vs CHIX:PHMe: 7.00

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharma Mar's adjusted revenue per share data for the three months ended in Sep. 2024 was €2.628. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €9.54 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Mar Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Pharma Mar's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Cyclically Adjusted PS Ratio Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.80 7.52 5.61 5.99 3.72

Pharma Mar Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.92 3.72 2.58 2.83 4.46

Competitive Comparison of Pharma Mar's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PS Ratio falls into.



Pharma Mar Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pharma Mar's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=68.825/9.54
=7.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Pharma Mar's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=2.628/123.1207*123.1207
=2.628

Current CPI (Sep. 2024) = 123.1207.

Pharma Mar Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 3.125 100.251 3.838
201503 2.496 99.474 3.089
201506 2.696 101.138 3.282
201509 2.832 99.559 3.502
201512 2.507 100.268 3.078
201603 2.287 98.638 2.855
201606 2.709 100.333 3.324
201609 2.575 99.737 3.179
201612 2.244 101.842 2.713
201703 2.469 100.896 3.013
201706 2.794 101.848 3.378
201709 1.464 101.524 1.775
201712 1.897 102.975 2.268
201803 1.510 102.122 1.820
201806 2.093 104.165 2.474
201809 1.214 103.818 1.440
201812 1.084 104.193 1.281
201903 1.053 103.488 1.253
201906 1.191 104.612 1.402
201909 1.142 103.905 1.353
201912 1.262 105.015 1.480
202003 5.380 103.469 6.402
202006 3.791 104.254 4.477
202009 2.922 103.521 3.475
202012 2.639 104.456 3.111
202103 2.824 104.857 3.316
202106 2.613 107.102 3.004
202109 2.312 107.669 2.644
202112 4.969 111.298 5.497
202203 2.953 115.153 3.157
202206 2.667 118.044 2.782
202209 2.437 117.221 2.560
202212 2.806 117.650 2.936
202303 1.891 118.948 1.957
202306 2.571 120.278 2.632
202309 2.105 121.343 2.136
202312 2.296 121.300 2.330
202403 2.168 122.762 2.174
202406 2.444 124.409 2.419
202409 2.628 123.121 2.628

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharma Mar  (CHIX:PHMe) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pharma Mar Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar Business Description

Industry
Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar Headlines

No Headlines